Dual acting and pan-PPAR activators as potential anti-diabetic therapies.
Level 5 - mechanism / opinion, no new human data
Narrative review of pharmacologic mechanisms and drug development without systematic review methodology
PubMed 21484566 · doi:10.1007/978-3-642-17214-4_2
What was done
This narrative review evaluated the pharmacological rationale, clinical experience, and drug development safety hurdles of single, dual (PPAR-α/γ, PPAR-α/δ), and pan-PPAR agonists for the management of type 2 diabetes and dyslipidemia.
What was found
The abstract reports no numerical data. Mechanistically, PPAR-γ agonists reduce insulin resistance and TNFα while raising adiponectin, but cause fluid retention and fat accumulation. PPAR-α agonists reduce triglycerides and increase HDL-cholesterol, and PPAR-δ agonists promote skeletal muscle fat oxidation. Although dual PPAR-α/γ agonists improved both glycemic control and lipid profiles, clinical development was broadly terminated due to adverse outcomes including weight gain, edema, increased plasma creatinine, myocardial infarction, stroke, and rodent carcinogenicity findings reported by the FDA. The author suggests shifting focus toward subtype-selective partial agonists, pathway-selective modulators, or low-affinity nutrient/lipid agonists.
Why it matters
It summarizes why early dual- and pan-PPAR drug development programs failed, highlighting the necessity of selective modulation or partial agonism to avoid lethal cardiovascular and oncologic toxicities.
Limits
As a narrative review, it lacks a systematic search protocol, quality assessment, and pooled quantitative data. No specific incidence rates, relative risks, or patient sample sizes are provided in the abstract.
Cited by
- supports Development of Cardarine (GW501516) was halted because animal studies showed a signal of cancer.